{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:45:14Z","timestamp":1761860714352,"version":"build-2065373602"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.otc.2023.08.006","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T06:26:47Z","timestamp":1694240807000},"page":"225-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps"],"prefix":"10.1016","volume":"57","author":[{"given":"Hanna K.","family":"Mandl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessa E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Beswick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.otc.2023.08.006_bib1","doi-asserted-by":"crossref","first-page":"g5517","DOI":"10.1136\/bmj.g5517","article-title":"Asthma: pathogenesis and novel drugs for treatment","volume":"349","author":"Olin","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.12701\/yujm.2020.00647","article-title":"Biological treatments for severe asthma","volume":"37","author":"Jin","year":"2020","journal-title":"Yeungnam Univ J Med"},{"issue":"260","key":"10.1016\/j.otc.2023.08.006_bib4","first-page":"1","article-title":"Summary health statistics for U.S. adults: national health interview survey, 2012","volume":"10","author":"Blackwell","year":"2014","journal-title":"Vital Health Stat"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0194599818774006","article-title":"Prevalence of Potential Adult Chronic Rhinosinusitis Symptoms in the United States","volume":"159","author":"Bhattacharyya","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2500\/ajra.2012.26.3741","article-title":"Chronic rhinosinusitis, race, and ethnicity","volume":"26","author":"Soler","year":"2012","journal-title":"Am J Rhinol Allergy"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/all.13042","article-title":"Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample","volume":"72","author":"Hirsch","year":"2017","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2500\/ajra.2016.30.4297","article-title":"Chronic rhinosinusitis: Epidemiology and burden of disease","volume":"30","author":"DeConde","year":"2016","journal-title":"Am J Rhinol Allergy"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/all.12577","article-title":"Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities","volume":"70","author":"Shi","year":"2015","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1398-9995.2005.00688.x","article-title":"Prevalence of nasal polyposis in France: a cross-sectional, case-control study","volume":"60","author":"Klossek","year":"2005","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/28.4.717","article-title":"Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study","volume":"28","author":"Hedman","year":"1999","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.otc.2023.08.006_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/000348940311200709","article-title":"Prevalence of nasal polyps in adults: the Sk\u00f6vde population-based study","volume":"112","author":"Johansson","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamaoto.2015.3142","article-title":"Prevalence and Risk Factors of Chronic Rhinosinusitus, Allergic Rhinitis, and Nasal Septal Deviation: Results of the Korean National Health and Nutrition Survey 2008-2012","volume":"142","author":"Ahn","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9643","key":"10.1016\/j.otc.2023.08.006_bib16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12016-019-08760-x","article-title":"Asthma Phenotypes as a Guide for Current and Future Biologic Therapies","volume":"59","author":"Hamilton","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"26","key":"10.1016\/j.otc.2023.08.006_bib18","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.otc.2023.08.006_bib19","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.otc.2023.08.006_bib20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","article-title":"Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology","volume":"131","author":"Akdis","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib21","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.jaci.2018.02.002","article-title":"Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines","volume":"141","author":"Turner","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/alr.21904","article-title":"Unsupervised network mapping of commercially available immunoassay yields three distinct chronic rhinosinusitis endotypes","volume":"7","author":"Divekar","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"issue":"7","key":"10.1016\/j.otc.2023.08.006_bib23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/all.13411","article-title":"Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes","volume":"73","author":"Liao","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.otc.2023.08.006_bib24","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3389\/fimmu.2018.02065","article-title":"Inflammatory Endotypes and Microbial Associations in Chronic Rhinosinusitis","volume":"9","author":"Hoggard","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/medicina55040095","article-title":"Inflammation and Endotyping in Chronic Rhinosinusitis-A Paradigm Shift","volume":"55","author":"Ahern","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib26","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"issue":"5 Suppl","key":"10.1016\/j.otc.2023.08.006_bib27","first-page":"S75","article-title":"Asthma and the unified airway","volume":"136","author":"Krouse","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otc.2022.09.001","article-title":"Unified Airway Disease: A Contemporary Review and Introduction","volume":"56","author":"Fokkens","year":"2023","journal-title":"Otolaryngol Clin North Am"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.otc.2022.09.014","article-title":"Unified Airway Disease: Future Directions","volume":"56","author":"Ahmad","year":"2023","journal-title":"Otolaryngol Clin North Am"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib30","first-page":"Cd013513","article-title":"Biologics for chronic rhinosinusitis","volume":"3","author":"Chong","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"10.1016\/j.otc.2023.08.006_bib33","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","article-title":"Omalizumab for asthma","volume":"354","author":"Strunk","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/1744666X.2019.1574571","article-title":"Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018","volume":"15","author":"MacDonald","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.otc.2023.08.006_bib35","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14740338.2017.1286327","article-title":"The safety of mepolizumab for the treatment of asthma","volume":"16","author":"Leung","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"9248","key":"10.1016\/j.otc.2023.08.006_bib37","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.otc.2023.08.006_bib38","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A\u00a0study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.otc.2023.08.006_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.otc.2023.08.006_bib40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1378\/chest.11-0618","article-title":"Point: Is Measuring Sputum Eosinophils Useful Management Severe Asthma? Yes","volume":"139","author":"Hargreave","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/13543784.2017.1282458","article-title":"Dupilumab for the treatment of asthma","volume":"26","author":"Santini","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MCP.0000000000000225","article-title":"Asthma phenotypes and endotypes: a personalized approach to treatment","volume":"22","author":"Skloot","year":"2016","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/ph16020270","article-title":"Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future","volume":"16","author":"Ram\u00edrez-Jim\u00e9nez","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9842","key":"10.1016\/j.otc.2023.08.006_bib44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.otc.2023.08.006_bib45","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.otc.2023.08.006_bib46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.otc.2023.08.006_bib47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.otc.2023.08.006_bib48","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib50","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.otc.2023.08.006_bib53","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2017.1316194","article-title":"Benralizumab for the treatment of asthma","volume":"13","author":"Saco","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.otc.2023.08.006_bib55","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib56","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.otc.2023.08.006_bib57","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A\u00a0randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"10056","key":"10.1016\/j.otc.2023.08.006_bib59","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.otc.2023.08.006_bib60","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.otc.2023.08.006_bib61","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2147\/TCRM.S157171","article-title":"Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use","volume":"14","author":"Maselli","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"25","key":"10.1016\/j.otc.2023.08.006_bib62","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.otc.2023.08.006_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: a novel treatment for asthma","volume":"7","author":"Vatrella","year":"2014","journal-title":"J\u00a0Asthma Allergy"},{"issue":"26","key":"10.1016\/j.otc.2023.08.006_bib64","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10039","key":"10.1016\/j.otc.2023.08.006_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.otc.2023.08.006_bib66","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.otc.2023.08.006_bib68","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/JAA.S378062","article-title":"Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis","volume":"15","author":"Zoumot","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.coph.2008.03.002","article-title":"Thymic stromal lymphopoietin: a new cytokine in asthma","volume":"8","author":"Rochman","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"10.1016\/j.otc.2023.08.006_bib70","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.otc.2023.08.006_bib71","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1016\/j.jaip.2021.07.045","article-title":"Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy","volume":"9","author":"Corren","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","article-title":"Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent","volume":"7","author":"Krings","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.otc.2023.08.006_bib74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-2600(18)30291-1","article-title":"Urgent need for pragmatic trial platforms in severe asthma","volume":"6","author":"Pilette","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib75","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","article-title":"Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update","volume":"33","author":"Levy","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"issue":"10","key":"10.1016\/j.otc.2023.08.006_bib78","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and Difficult-to-Treat Asthma in Adults","volume":"377","author":"Israel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib79","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaip.2020.10.048","article-title":"How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit","volume":"9","author":"Pepper","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.otc.2023.08.006_bib80","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.jaip.2021.02.031","article-title":"Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics","volume":"9","author":"Jeffery","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.otc.2023.08.006_bib81","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.otc.2023.08.006_bib82","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.2147\/DDDT.S226575","article-title":"Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy","volume":"14","author":"Kariyawasam","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.otc.2023.08.006_bib83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.otc.2023.08.006_bib84","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.otc.2023.08.006_bib85","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/1744666X.2021.1847083","article-title":"Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4R\u03b1 inhibition with dupilumab","volume":"16","author":"Kariyawasam","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"10209","key":"10.1016\/j.otc.2023.08.006_bib86","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.otc.2023.08.006_bib87","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib88","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/alr.23059","article-title":"A\u00a0comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Miglani","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"10.1016\/j.otc.2023.08.006_bib89","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jaip.2022.02.017","article-title":"Biologicals and Endoscopic Sinus Surgery for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: An Economic Perspective","volume":"10","author":"van der Lans","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.otc.2023.08.006_bib90","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/alr.22976","article-title":"Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population","volume":"12","author":"Rathi","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"11","key":"10.1016\/j.otc.2023.08.006_bib91","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/alr.22864","article-title":"Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics","volume":"11","author":"Roland","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"10.1016\/j.otc.2023.08.006_bib92","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.otc.2023.08.006_bib93","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.otc.2023.08.006_bib95","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/JAA.S354062","article-title":"Use of Biologic Therapies in the Treatment of Asthma - A Comparative Real World Data Analysis on Healthcare Resource Utilization and Costs Before and After Therapy Initiation","volume":"15","author":"Hardtstock","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib96","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12931-023-02372-y","article-title":"Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study","volume":"24","author":"Faverio","year":"2023","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib97","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2500\/aap.2021.42.200101","article-title":"Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations","volume":"42","author":"Dudiak","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"12","key":"10.1016\/j.otc.2023.08.006_bib98","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0960327115603594","article-title":"A\u00a0snapshot of biologic drug development: Challenges and opportunities","volume":"34","author":"Andrews","year":"2015","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib99","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.otc.2023.08.006_bib100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1753465817717134","article-title":"Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects","volume":"11","author":"M\u00e1spero","year":"2017","journal-title":"Ther Adv Respir Dis"},{"issue":"12","key":"10.1016\/j.otc.2023.08.006_bib101","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jsps.2022.10.002","article-title":"Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies","volume":"30","author":"Moni","year":"2022","journal-title":"Saudi Pharm J"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib102","doi-asserted-by":"crossref","first-page":"1901208","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/all.14282","article-title":"Biologicals in atopic disease in pregnancy: An EAACI position paper","volume":"76","author":"Pfaller","year":"2021","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.otc.2023.08.006_bib104","first-page":"e24641","article-title":"Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis","volume":"14","author":"Jahangir","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13223-022-00676-0","article-title":"The new era of add-on asthma treatments: where do we stand?","volume":"18","author":"Calhoun","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib106","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib107","doi-asserted-by":"crossref","first-page":"AB270","DOI":"10.1016\/j.jaci.2017.12.860","article-title":"Efficacy of Reslizumab in Eosinophilic Chronic Sinusitis with Nasal Polyposis","volume":"141","author":"Kuruvilla","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib108","doi-asserted-by":"crossref","first-page":"AB17","DOI":"10.1016\/j.jaci.2022.12.058","article-title":"Tezepelumab Efficacy By SNOT-22 Score In Patients With Severe, Uncontrolled Asthma And Comorbid Nasal Polyps In NAVIGATOR","volume":"151","author":"Jacobs","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.otc.2023.08.006_bib109","unstructured":"Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). 2023 2023-06-23 cited 2023 2023-8-7; Available at: https:\/\/clinicaltrials.gov\/study\/NCT04851964?term=tezepelumab&page=2&rank=11."},{"issue":"10","key":"10.1016\/j.otc.2023.08.006_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105523","article-title":"Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets","volume":"23","author":"Tai","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib111","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2332\/allergolint.13-OA-0572","article-title":"Increased CXCL10 expression in nasal fibroblasts from patients with refractory chronic rhinosinusitis and asthma","volume":"62","author":"Yoshikawa","year":"2013","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.otc.2023.08.006_bib112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MAJ.0b013e3181f20489","article-title":"Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis","volume":"341","author":"Liu","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.otc.2023.08.006_bib113","first-page":"Cd003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib114","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.otc.2023.08.006_bib115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.otc.2023.08.006_bib116","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.otc.2023.08.006_bib117","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.otc.2023.08.006_bib118","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/TCRM.S210648","article-title":"Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date","volume":"16","author":"Kim","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"10.1016\/j.otc.2023.08.006_bib119","first-page":"e32156","article-title":"The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials","volume":"14","author":"Roy","year":"2022","journal-title":"Cureus"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666523001536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666523001536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:56:32Z","timestamp":1758466592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666523001536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0030666523001536"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2023.08.006","relation":{},"ISSN":["0030-6665"],"issn-type":[{"type":"print","value":"0030-6665"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2023.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}